SEARCH

SEARCH BY CITATION

References

  • Albers D. S. and Sonsalla P. K. (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275, 11041114.
  • Ali S. F., Newport G. D., Holson R. R., Slikker W. Jr and Bowyer J. F. (1994) Low environmental temperature or pharmacologica agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice. Brain Res. 658, 3338.
  • Andersson J. L., Marcus M., Nomikos G. G. and Svensson T. H. (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedebergs Arch. Pharmacol. 349, 236243.
  • Auclair A., Cotecchia S., Glowinski J. and Tassin J. P. (2002) d-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J. Neurosci. 22, 91509154.
  • Battaglia G., Fornai F., Busceti L. C., Aloisi G., Cerrito F., De Blasi A., Melchiorri D. and Nicoletti F. (2002) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22, 21352141.
  • Bedard M. A., El Massioui F., Malapani C., Dubois B., Pillon B., Renault B. and Agid Y. (1998) Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin. Neuropharmacol. 21, 108117.
  • Bing G., Zhang Y., Watanabe Y., McEwen B. S. and Stone E. A. (1994) Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668, 261265.
  • Bowyer J. F., Davies D. L., Schmued L., Broening H. W., Newport G. D., Slikker W. Jr and Holson R. R. (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268, 15711580.
  • Cavalli A., Lattion A. L., Hummler E., Nenniger M., Pedrazzini T., Aubert J. F., Michel M. C., Yang M., Lembo G., Vecchione C., Mostardini M., Schmidt A., Beermann F. and Cotecchia S. (1997) Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc. Natl Acad. Sci. USA 94, 1158911594.
  • Cho A. K., Melega W. P., Kuczenski R. and Segal D. S. (2001) Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39, 161166.
  • Cubells J. F., Rayport S., Rajendran G. and Sulzer D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14, 22602271.
  • Davidson C., Gow A. J., Lee H. T. and Ellinwood H. E. (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Rev. 36, 122.
  • Drouin C., Darracq L., Trovero F., Blanc G., Glowinski J., Cotecchia S. and Tassin J. P. (2002) α-1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. 22, 28732884.
  • Eisch A. J., Gaffney M., Weihmuller F. B., O'Dell S. J. and Marshall J. F. (1992) Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598, 321326.
  • Fornai F., Bassi L., Torracca M. T., Scalori V. and Corsini G. U. (1995) Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283, 99102.
  • Fornai F., Giorgi F. S., Alessandri M. G., Giusiani M. and Corsini G. U. (1999) Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72, 777784.
  • Franklin K. B. J. and Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, London.
  • Gerlach M. and Riederer P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103, 9871041.
  • Gesi M., Soldani P., Giorgi F. S., Santinami A., Bonaccorsi I. and Fornai F. (2000) The role of locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24, 655668.
  • Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265275.
  • Marien M., Briley M. and Colpaert F. (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236, 487489.
  • Mavridis M., Degryse A. D., Lategan A. J., Marien M. R. and Colpaert F. C. (1991a) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507523.
  • Mavridis M., Colpaert F. C. and Millan M. J. (1991b) Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res. 562, 216224.
  • McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F. and Ricaurte G. A. (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 84178422.
  • Miller D. B. and O'Callaghan J. P. (1994) Environment-drug- and stress-induced alterations in body temperature affects the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 752760.
  • O'Dell S. J., Weihmuller F. B. and Marshall J. F. (1991) Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564, 256260.
  • Paladini C. A., Fiorillo C. D., Morikawa H. and Williams J. T. (2001) Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons. Nature Neurosci. 4, 275281.
  • Przedborski S. and Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov. Disord. 13, 3538.
  • Pu C. and Vorhees C. V. (1993) Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocytes reaction in rat striatum. Brain Res. 72, 325328.
  • Ricaurte G. A. and McCann U. D. (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. NY Acad. Sci. 648, 371382.
  • Ricaurte G. A., Guillery R. W., Seiden L. S., Schuster C. R. and Moore R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93103.
  • Ricaurte G. A., Seiden L. S. and Schuster C. R. (1984) Further evidence that amphetamine produced long lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303, 358364.
  • Sommermeyer H., Frielingsdorf J. and Knorr A. (1995) Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur. J. Pharmacol. 276, 267270.
  • Sonsalla P. K., Jochnowitz N. D., Zeevalk G. D., Oostveen J. A. and Hall E. D. (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738, 172175.
  • Villemagne V., Yuan J., Wong D. F., Dannals R. F., Hatzidimitriou G., Mathews W. B., Ravert H. T., Musachio J., McCann U. D. and Ricaurte G. A. (1998) Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18, 419427.
  • Volkow N. D., Chang L., Wang G. J., Fowler J. S., Franceschi D., Sedler M., Gatley S. J., Miller E., Hitzemann R., Ding Y. S. and Logan J. (2001a) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21, 94149418.
  • Volkow N. D., Chang L., Wang G. J., Fowler J. S., Leonido-Yee M., Franceschi D., Sedler M. J., Gatley S. J., Hitzemann R., Ding Y. S., Logan J., Wong C. and Miller E. N. (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158, 377382.
  • Wagner G. C., Lucot J. B., Schuster C. R. and Seiden L. S. (1981) The ontogeny of aggregation-enhanced toxicity. Psychopharmacology 75, 9293.
  • Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W. and Kish S. J. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2, 699703.
  • Woolverton W. L., Ricaurte G. A., Forno L. S. and Seiden L. S. (1989) Long-term effects of chronic methamphetamine administration in rhesus monkey. Brain Res. 486, 7378.
  • Zuscik M. J., Sands S., Ross S. A., Waugh D. J., Gaivin R. J., Morilak D. and Perez D. M. (2000) Overexpression of the alpha-1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nature Med. 6, 13881394.